Immutep (XTER:YP1A) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Immutep Days Payable?

Immutep's average Accounts Payable for the three months ended in Dec. 2023 was €1.86 Mil. Immutep's Cost of Goods Sold for the three months ended in Dec. 2023 was €0.00 Mil.

The historical rank and industry rank for Immutep's Days Payable or its related term are showing as below:

XTER:YP1A's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.29
* Ranked among companies with meaningful Days Payable only.

Immutep's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Immutep Days Payable Historical Data

The historical data trend for Immutep's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Days Payable Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Payable

Get a 7-Day Free Trial

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immutep's Days Payable

For the Biotechnology subindustry, Immutep's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Days Payable distribution charts can be found below:

* The bar in red indicates where Immutep's Days Payable falls into.

Immutep Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Immutep's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (1.905	+	3.375)	/	2 )	/	0	*	365
=	2.64					/	0	*	365
=	N/A

Immutep's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0	+	1.862)	/	1 )	/	0	*	365 / 4
=	1.862					/	0	*	365 / 4
=	N/A

Immutep Days Payable Related Terms

Thank you for viewing the detailed overview of Immutep's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (XTER:YP1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines